BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 14499144)

  • 1. Anatomolecular imaging with 2-deoxy-2-[18F]fluoro-D-glucose: bench to outpatient center.
    Wahl RL
    Mol Imaging Biol; 2003; 5(2):49-56. PubMed ID: 14499144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical usefulness of FDG-PET in oncology].
    Sasaki M
    Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) in diagnosis of neoplastic diseases].
    Ruiz Hernández G; Romero de Avila Y Avalos C; Carreras Delgado JL
    Med Clin (Barc); 2005 Feb; 124(6):229-36. PubMed ID: 15737307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.
    Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE
    Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.
    Kubota K
    Ann Nucl Med; 2001 Dec; 15(6):471-86. PubMed ID: 11831394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D-glucose.
    Tatsumi M; Nakamoto Y; Traughber B; Marshall LT; Geschwind JF; Wahl RL
    Cancer Res; 2003 Oct; 63(19):6252-7. PubMed ID: 14559811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. False-positive uptake on 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging.
    Culverwell AD; Scarsbrook AF; Chowdhury FU
    Clin Radiol; 2011 Apr; 66(4):366-82. PubMed ID: 21356398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rate-limiting step for tumor [18F]fluoro-2-deoxy-D-glucose (FDG) incorporation.
    Smith TA
    Nucl Med Biol; 2001 Jan; 28(1):1-4. PubMed ID: 11182558
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An introduction to PET-CT imaging.
    Kapoor V; McCook BM; Torok FS
    Radiographics; 2004; 24(2):523-43. PubMed ID: 15026598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET-CT evaluation of 2-deoxy-2-[18F]fluoro-D-glucose myocardial uptake: effect of respiratory motion.
    Chin BB; Nakamoto Y; Kraitchman DL; Marshall L; Wahl R
    Mol Imaging Biol; 2003; 5(2):57-64. PubMed ID: 14499145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of tumor response using [18F]-2-fluoro-2-deoxy-D-glucose and positron-emission tomography.
    Lammertsma AA
    J Clin Pharmacol; 2001 Jul; 41(S7):104S-106S. PubMed ID: 11452713
    [No Abstract]   [Full Text] [Related]  

  • 13. [Uptake of FDG (2-fluoro-2-deoxy-D-glucose) as a tumor imaging agent into erythrocytes and accumulation of FDG in tumor cells].
    Minosako Y; Nemoto M; Ino S; Shirakami Y; Kurami M
    Kaku Igaku; 2003 Feb; 40(1):23-30. PubMed ID: 12701204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of extracranial radioactivity on measurement of cerebral glucose metabolism by rat-PET with [18F]-2-fluoro-2-deoxy-D-glucose.
    Kuge Y; Miyake Y; Minematsu K; Yamaguchi T; Hasegawa Y
    J Cereb Blood Flow Metab; 1997 Nov; 17(11):1261-2. PubMed ID: 9390658
    [No Abstract]   [Full Text] [Related]  

  • 15. Quantification in clinical fluorodeoxyglucose positron emission tomography.
    Hallett WA
    Nucl Med Commun; 2004 Jul; 25(7):647-50. PubMed ID: 15208490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
    Endo K; Oriuchi N; Higuchi T; Iida Y; Hanaoka H; Miyakubo M; Ishikita T; Koyama K
    Int J Clin Oncol; 2006 Aug; 11(4):286-96. PubMed ID: 16937302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pivotal role of FDG-PET/CT in modern medicine.
    Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
    Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The contribution of PET to radiation treatment planning].
    Belkacémi Y; Lartigau E; Kerrou K; Carpentier P; Taïeb S; Giraud P
    Bull Cancer; 2007 Jan; 94(1):99-108. PubMed ID: 17237010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined imaging modalities: PET/CT and SPECT/CT.
    Maurer AH
    Health Phys; 2008 Nov; 95(5):571-6. PubMed ID: 18849691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma.
    Hoffmann M; Vogelsang H; Kletter K; Zettinig G; Chott A; Raderer M
    Gut; 2003 Mar; 52(3):347-51. PubMed ID: 12584214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.